To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
Public ClinicalTrials.gov record NCT02596451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc) in Patients With Osteoarthritis (OA) of the Knee
Study identification
- NCT ID
- NCT02596451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. India
- Industry
- Enrollment
- 1,164 participants
Conditions and interventions
Conditions
Interventions
- Diclofenac Sodium gel, 1% Drug
- Voltaren® Gel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Feb 29, 2016
- Completion
- Feb 29, 2016
- Last update posted
- Jun 27, 2017
2015 – 2016
United States locations
- U.S. sites
- 44
- U.S. states
- 14
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Glenmark Investigational Site 5 | Mesa | Arizona | — | — |
| Glenmark Investigational Site 1 | Anaheim | California | — | — |
| Glenmark Investigational Site 21 | Anaheim | California | — | — |
| Glenmark Investigational Site 31 | Anaheim | California | — | — |
| Glenmark Investigational Site 26 | Canoga Park | California | — | — |
| Glenmark Investigational Site 42 | Carlsbad | California | — | — |
| Glenmark Investigational Site 30 | Carmichael | California | — | — |
| Glenmark Investigational Site 33 | Cerritos | California | — | — |
| Glenmark Investigational Site 25 | El Cajon | California | — | — |
| Glenmark Investigational Site 24 | La Mesa | California | — | — |
| Glenmark Investigational Site 2 | Pasadena | California | — | — |
| Glenmark Investigational Site 13 | Rancho Cucamonga | California | — | — |
| Glenmark Investigational Site 27 | Sacramento | California | — | — |
| Glenmark Investigational Site 10 | Fort Lauderdale | Florida | — | — |
| Glenmark Investigational Site 41 | Hialeah | Florida | — | — |
| Glenmark Investigational Site 15 | Miami | Florida | — | — |
| Glenmark Investigational Site 19 | Miami | Florida | — | — |
| Glenmark Investigational Site 28 | Miami | Florida | — | — |
| Glenmark Investigational Site 32 | Miami | Florida | — | — |
| Glenmark Investigational Site 40 | Miami | Florida | — | — |
| Glenmark Investigational Site 3 | Miami Lakes | Florida | — | — |
| Glenmark Investigational Site 37 | Ormond Beach | Florida | — | — |
| Glenmark Investigational Site 11 | West Palm Beach | Florida | — | — |
| Glenmark Investigational Site 18 | West Palm Beach | Florida | — | — |
| Glenmark Investigational Site 8 | Evanston | Illinois | — | — |
| Glenmark Investigational Site 43 | Newburgh | Indiana | — | — |
| Glenmark Investigational Site 38 | Wichita | Kansas | — | — |
| Glenmark Investigational Site 17 | New Orleans | Louisiana | — | — |
| Glenmark Investigational Site 22 | Saginaw | Michigan | — | — |
| Glenmark Investigational Site 14 | St Louis | Missouri | — | — |
| Glenmark Investigational Site 9 | Englewood | Ohio | — | — |
| Glenmark Investigational Site7 | Altoona | Pennsylvania | — | — |
| Glenmark Investigational Site 36 | Knoxville | Tennessee | — | — |
| Glenmark Investigational Site 39 | Nashville | Tennessee | — | — |
| Glenmark Investigational Site 23 | Beaumont | Texas | — | — |
| Glenmark Investigational Site 20 | Bryan | Texas | — | — |
| Glenmark Investigational Site 34 | Dallas | Texas | — | — |
| Glenmark Investigational Site 35 | Houston | Texas | — | — |
| Glenmark Investigational Site 44 | Houston | Texas | — | — |
| Glenmark Investigational Site 4 | Lampasas | Texas | — | — |
| Glenmark Investigational Site 29 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 6 | San Antonio | Texas | — | — |
| Glenmark Investigational Site 16 | Charlottesville | Virginia | — | — |
| Glenmark Investigational Site12 | Midlothian | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02596451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02596451 live on ClinicalTrials.gov.